Hana plans to raise $100M for FDA app; FDA puts Chelsea trial on hold; new rounds for European developers;

 @FierceBiotech: Forest Labs scoops up diabetes programs in $1.1B TransTech deal. Report | Follow @FierceBiotech

 @JohnCFierce: Myriad is axing 21 staffers, suspending an HIV program and concentrating on cancer in restructuring. Report | Follow @JohnCFierce

> Hana Biosciences is planning to raise up to $100 million from Warburg Pincus and Deerfield Management to fund its FDA application for the leukemia drug Marqibo. Report

> Chelsea Therapeutics says the FDA is temporarily putting its planned Phase II study for the rheumatoid arthritis drug CH-4051 on ice as it seeks information on its preclinical program. Chelsea says it can provide the needed data. Chelsea release

> Paris-based Pharnext says it raised a 4.8-million euro Series A to help fund its work on new drugs for neurological diseases. Pharnext release

> Denmark's Action Pharma raised €5 million in a new round. Sunstone Capital, Global Life Science Ventures, SLS Invest and InnovationsKapital all contributed to the round. Action release

> An FDA panel is scheduled to meet June 17 to review a new morning after pill from Paris-based HRA Pharma. The pill, effective up to five days after intercourse, is already available in Europe. Story

And Finally... Researchers at MIT's McGovern Institute for Brain Research have developed a new mathematical model to describe how the human brain visually identifies objects. Report

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.